WO2023177841A3 - Combination products to mitigate misuse of central nervous system stimulants - Google Patents

Combination products to mitigate misuse of central nervous system stimulants Download PDF

Info

Publication number
WO2023177841A3
WO2023177841A3 PCT/US2023/015455 US2023015455W WO2023177841A3 WO 2023177841 A3 WO2023177841 A3 WO 2023177841A3 US 2023015455 W US2023015455 W US 2023015455W WO 2023177841 A3 WO2023177841 A3 WO 2023177841A3
Authority
WO
WIPO (PCT)
Prior art keywords
misuse
effective amount
mitigate
nervous system
combination products
Prior art date
Application number
PCT/US2023/015455
Other languages
French (fr)
Other versions
WO2023177841A2 (en
Inventor
Michael PRESTI
Original Assignee
Presti Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presti Michael filed Critical Presti Michael
Publication of WO2023177841A2 publication Critical patent/WO2023177841A2/en
Publication of WO2023177841A3 publication Critical patent/WO2023177841A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method is provided for reducing concurrent use of stimulant medications and alcohol. In an example, the method comprises administering to the subject a combination product that includes an effective amount of one or more stimulant medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors (ALDIs), to provide the desired effects of the stimulant medication in conjunction with a substance that prevents or deters concurrent alcohol consumption, thereby reducing misuse of stimulant medications in combination with alcohol. Also disclosed are the combination products that include the effective amount of one or more stimulant medications and the effective amount of one or more ALDIs.
PCT/US2023/015455 2022-03-18 2023-03-17 Combination products to mitigate misuse of central nervous system stimulants WO2023177841A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321221P 2022-03-18 2022-03-18
US63/321,221 2022-03-18

Publications (2)

Publication Number Publication Date
WO2023177841A2 WO2023177841A2 (en) 2023-09-21
WO2023177841A3 true WO2023177841A3 (en) 2023-10-19

Family

ID=88024197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/015455 WO2023177841A2 (en) 2022-03-18 2023-03-17 Combination products to mitigate misuse of central nervous system stimulants

Country Status (1)

Country Link
WO (1) WO2023177841A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281112A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
US20160213628A1 (en) * 2013-09-09 2016-07-28 Nova Southeastern University Deterring abuse of pharmaceutical products and alcohol
US20190231719A1 (en) * 2018-01-26 2019-08-01 Michael Presti Combination treatments for opioid crisis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
US20090281112A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
US20160213628A1 (en) * 2013-09-09 2016-07-28 Nova Southeastern University Deterring abuse of pharmaceutical products and alcohol
US20190231719A1 (en) * 2018-01-26 2019-08-01 Michael Presti Combination treatments for opioid crisis

Also Published As

Publication number Publication date
WO2023177841A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
Brideau et al. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐α and leukotriene B4 in a novel human whole blood assay
Dehesa et al. Treatment of inflammatory nail disorders
Song et al. Involvement of miR-Let7A in inflammatory response and cell survival/apoptosis regulated by resveratrol in THP-1 macrophage
McAlindon et al. Nutritional factors and osteoarthritis: recent developments
Kato et al. Metformin attenuates production of nitric oxide in response to lipopolysaccharide by inhibiting MyD88-independent pathway
AU2021469614A1 (en) Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis
Prachanpanich et al. A comparison of dexmedetomidine and propofol in Patients undergoing electrophysiology study
Kelly et al. Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?
WO2023177841A3 (en) Combination products to mitigate misuse of central nervous system stimulants
Penning et al. Caffeinated drinks, alcohol consumption, and hangover severity
Congiu et al. N-acylethanolamine acid amidase inhibition potentiates morphine analgesia and delays the development of tolerance
Hashimoto et al. Prurigo successfully treated with duloxetine hydrochloride
Borja-Oliveira Alcohol-medication interactions: the acetaldehyde syndrome
Ghisalberti et al. Soft TCPTP Agonism—Novel Target to Rescue Airway Epithelial Integrity by Exogenous Spermidine
MX2020007860A (en) Combination treatments for opioid crisis.
Davicino et al. Different activities of Schinus areira L.: anti-inflammatory or pro-inflammatory effect
Nofal et al. Low‐dose oral isotretinoin for the treatment of warts: A controversial issue.
ALSUntangled Group ALSUntangled no. 16: cannabis
Zhang et al. Metformin induction of fetal hemoglobin
Gurguis et al. Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)
Guliani et al. Type 2 diabetic female with vildagliptin associated eczematous eruption
Chen et al. Ashwagandha and Its Active Ingredient, Withanolide A, Increase Phosphorylation of TrkB in Cultured Hippocampal Neurons
Choi et al. Carbon monoxide-releasing molecule-401, a water-soluble manganese-based metal carbonyl, suppresses Prevotella intermedia lipopolysaccharide-induced production of nitric oxide in murine macrophages
Luo et al. De-Escalation or Discontinuation of TKI in Patients with Chronic Myeloid Leukemia: a Multicentral, Open-Lable, Prospective Trial in China
Ferng et al. RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771436

Country of ref document: EP

Kind code of ref document: A2